skip to primary navigationskip to content
 

Owlstone Medicals ReCIVA technology Invention of the Year in Top 50 Digital Health Awards

last modified Jan 06, 2017 03:38 PM
Early diagnosis and health care savings winning combination
Owlstone Medicals ReCIVA technology Invention of the Year in Top 50 Digital Health Awards

Owlstone Medical’s Co-Founder and CEO, Billy Boyle, demonstrating the ReCIVA device.

ReCIVA, or Respiration Collector for In Vitro Analysis for short, meets the needs of a growing field of breath research but reliably and reproducibly capturing breath samples for analysis. In doing so, ReCIVA allows researchers to focus their efforts on analysing the captured samples and detect targeted biomarkers of disease in breath (and other bodily fluids). It can diagnose cancer and other diseases earlier than existing tests, allowing for more effective treatment and ultimately, improved survival rates and reduced treatment costs.

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “We are delighted that ReCIVA has been named Invention in the 2017 Top 50 Digital Health Awards. Our vision is to save 100,000 lives and $1.5B in health care costs by 2020 with a breath sampling and analysis technology that can diagnose cancer and other diseases earlier than existing tests. This allows for more effective treatment and ultimately, better patient survival rates and reduced treatment costs.”

About the Awards

Each year fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank.  

Within the Top 50, a number of individuals and organizations are awarded through nominations from the digital health community for making exceptional progress in driving resources, attention, and innovation toward a massively better healthcare system. From writing healthcare policy to steering corporate acquisitions to moving technology from the bench to the bedside, the Awards honor the people and organizations making digital health thrive.

About Owlstone Medical

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs by 2020.

The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids).  FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.

Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications. 

Founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge University, Owlstone Inc is a profitable business selling it’s proven FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialise FAIMS in diagnostic applications.

Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK. 

 

RSS Feed Latest news

Spotlight on Mursla

Feb 03, 2019

Cancer is one of the most challenging global issues an entrepreneur could choose to tackle. But Pierre Arsène and Victor Serdio are doing just that with their company Mursla. Based at ideaSpace West, Mursla is developing a breakthrough technology for early cancer detection using liquid biopsies, offering a less invasive and more responsive approach to diagnosis, treatment and cure. To mark World Cancer Day on the 4th February, we asked Pierre to explain more about Mursla and the bold ideas and enthusiasm driving this bright company.

LESSONS FROM A FOUNDER: What's Your 2019 Startup Goal?

Jan 30, 2019

For many of us, a new year often starts with an optimistic resolution to change – join the gym, write a book, travel perhaps. But if you’re running a startup, January is a great time to assess your company’s development and set fresh goals for the coming year. We asked four founders at ideaSpace to reflect on progress and share their area of focus for 2019.

GeoSpock Lands £10 Million in Additional Funding 

Jan 09, 2019

ideaSpace alumni and extreme data specialists, GeoSpock, have secured an extra  £10 million in funding. The latest round was led by Cambridge Innovation Capital (CIC) jointly with Parkwalk Advisors and Japanese firms Global Brain and 31Ventures. Japanese data tech company KDDI Supership joined as a strategic investor. Investment was also secured from existing investor, Jonathan Milner.

A Breath Test Could Detect Early Cancer Signs

Jan 06, 2019

CRUK and ideaSpace City members, Owlstone Medical, have launched a new trial to discover whether it's possible to detect early stage cancer symptoms from a person's breath.

Petagene secure $2.1 Million in Funding 

Jan 03, 2019

2019 is off to a great start for the Petagene team who have been awarded $2.1 million in additional funding. The latest round was lead by U.S. venture firm Romulus Capital, with collaboration from other unnamed investors in London and Silicon Valley, bringing the total funding awarded to $3.2 million.

View all news